Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology
Open Access
- 31 October 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (21), 5296-5302
- https://doi.org/10.1158/1078-0432.ccr-10-0669
Abstract
Purpose: Phase II clinical studies screen for treatment regimens that improve patient care, but screening combination regimens is especially challenging. We hypothesized that recognized flaws of single-arm trials could be magnified in combination treatment studies, leading to many reported positive phase II trials but with a low fraction resulting in practice-changing phase III trials. Experimental Design: We searched medline and identified 363 combination chemotherapy clinical trials published in 2001 and 2002. Studies were rated as positive, negative, or inconclusive based on a standardized review of abstract and text. The Web of Science Index (Thomson Reuters, NY, NY) was searched for all articles published between January 2003 and October 2007 that cited at least one of these 363 published trials. Results: Of 363 published phase II combination chemotherapy trials, 262 (72%) were declared to be positive. Among 3,760 unique subsequent citing papers, 20 reported randomized phase III trials of the same combination in the same disease as the source paper, and 10 of these resulted in improved standards of care. Estimating from these data, the likelihood that a published, positive phase II combination chemotherapy trial will result in a subsequent trial showing an improvement in standard of care within five years was 0.038 (95% confidence interval, 0.016-0.064). Conclusions: The contributory value of combination chemotherapy phase II trials done by 2001-2002 standards is low despite the participation of more than 16,000 subjects. Future phase II studies of combination regimens require better methods to screen for treatments most likely to improve standards of care. Clin Cancer Res; 16(21); 5296–302. ©2010 AACR.Keywords
This publication has 15 references indexed in Scilit:
- Novel Designs and End Points for Phase II Clinical TrialsClinical Cancer Research, 2009
- Optimising the design of phase II oncology trials: The importance of randomisationEuropean Journal of Cancer, 2009
- Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?Journal of Clinical Oncology, 2008
- Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase IIIJournal of Clinical Oncology, 2008
- Phase II Trials Published in 2002: A Cross-Specialty Comparison Showing Significant Design Differences between Oncology Trials and Other Medical SpecialtiesClinical Cancer Research, 2007
- Economics of New Oncology Drug DevelopmentJournal of Clinical Oncology, 2007
- Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic RegimensJournal of Clinical Oncology, 2005
- TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2Journal of Clinical Oncology, 2004
- Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials.American Heart Journal, 2000